Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial
Authors:
Open Access
- 4 March 2014
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 25 (5) , 987-991
Abstract
The standard treatment of patients with metastatic germ-cell tumor (GCT) relapsing after first-line chemotherapy is based on a cisplatin and ifosfamide-containing three-drug regimen, which usually yields a complete response (CR) rate 2 day 1 and 5, ifosfamide 1200 mg/m2/day day 1–5, cisplatin 20 mg/m2/day day 1–5, and granulocyte colony-stimulating factor 263 μg/day day 7–15, repeated every 3 weeks for four cycles. Eligibility criteria were that patients had favorable prognostic factors to conventional-dose salvage chemotherapy including a testis primary tumor and a previous CR to first-line chemotherapy for metastatic disease. The primary end point was the CR rate and a two-stage Simon design was used. Thirty-seven patients were accrued and 29 (78%) achieved a favorable response, including a CR in 20 (54%) and a partial response with normalization of tumor markers (PRm−) in 9 (24%). With a median follow-up of 53 months (13–81), the 2-year overall survival rate is 73% (57%–84%) and the continuous progression-free survival rate is 51% (35%–66%). Myelosuppression was the main toxicity including febrile neutropenia in 8 (22%) patients and 18 (50%) cases required platelet infusion. No grade 3 and 4 peripheral neurotoxicity or renal toxicity occurred. Two patients died of treatment-related toxicity, one of them with cancer progression. In a multicenter context, four cycles of the GIP regimen achieved a high CR rate in patients with relapsed testicular GCT. The GIP regimen avoided severe neurotoxicity and yielded a high survival rate. NCT00127049.Keywords
Funding Information
- Lilly France
- Chugai Pharma France
This publication has 32 references indexed in Scilit:
- Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancerAnnals of Oncology, 2012
- Sequential Versus Single High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: Long-Term Results of a Prospective Randomized TrialJournal of Clinical Oncology, 2012
- EAU Guidelines on Testicular Cancer: 2011 UpdateEuropean Urology, 2011
- Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International DatabaseJournal of Clinical Oncology, 2011
- Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line ChemotherapyJournal of Clinical Oncology, 2010
- High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell TumorsNew England Journal of Medicine, 2007
- A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumoursAnnals of Oncology, 2005
- Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trialAnnals of Oncology, 2005
- Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival.Journal of Clinical Oncology, 1997
- Salvage chemotherapy for patients with germ cell tumors. The memorial sloan-kettering cancer center experience (1979–1989)Cancer, 1991